Pharmacokinetics of cefepime in patients with thermal burn injury

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2848-2854

  Bonapace, Charles R ^a   White, Roger L ^a   Friedrich, Lawrence V ^a   Norcross, E Douglas ^b   Bosso, John A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BURN; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; INFECTION; KIDNEY CLEARANCE; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0032805939     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2848     Document Type: Article

References (37)

1. Adam, D., P. R. Zellner, P. Koeppe, and R. Wesch. 1989. Pharmacokinetics of ticarcillin/clavulanate in severely burned patients. J. Antimicrob. Chemother. 24(Suppl. B):121-130.
2. Bailie, G. R., B. H. Ackerman, J. Fischer, L. D. Solem, and J. C. Rotschafer. 1984. Increased vancomycin dosage requirements in young burn patients. J. Burn Care Rehabil. 5:376-378.
3. Barbhaiya, R. H., S. T. Forgue, W. C. Shyu, E. A. Papp, and K. A. Pittman. 1987. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob. Agents Chemother. 31:55-59.
4. Barbhaiya, R. H., S. T. Forgue, C. R. Gleason, C. A. Knupp, K. A. Pittman, D. J. Weidler, and R. R. Martin. 1990. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob. Agents Chemother. 34:1118-1122.
5. Barbhaiya, R. H., C. A. Knupp, and K. A. Pittman. 1992. Effects of age and gender on pharmacokinetics of cefepime. Antimicrob. Agents Chemother. 36:1181-1185.
6. Barbhaiya, R. H., S. T. Forgue, C. R. Gleason, C. A. Knupp, K. A. Pittman, D. J. Weidler, H. Movahhed, J. Tenney, and R. R. Martin. 1992. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36:552-557.
7. Bootman, J. L., A. I. Wertheimer, and D. Zaske. 1979. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J. Pharm. Sci. 68:267-272.
8. Boucher, B. A., W. L. Hickerson, D. A. Kuhl, A. M. Bombassaro, and G. S. Jaresko. 1990. Imipenem pharmacokinetics in patients with burns. Clin. Pharmacol. Ther. 48:130-137.
9. Boucher, B. A., D. A. Kuhl, and W. L. Hickerson, 1992. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin. Infect. Dis. 14:458-463.
10. Bourget, P., A. Lesne-Hulin, R. Le Reveillé, H. Le Bever, and H. Carsin. 1996. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob. Agents Chemother. 40:139-145.
11. Brater, D. C., R. E. Bawdon, S. A. Anderson, G. F. Purdue, and J. L. Hunt. 1986. Vancomycin elimination in patients with burn injury. Clin. Pharmacol. Ther. 39:631-634.
12. Cockroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
13. Craig, W. A. 1997. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
14. Cronqvist, J., I. Nilsson-Ehle, B. Öqvist, and S. R. Norrby. 1992. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob. Agents Chemother. 36:2676-2680.
15. Fox, J. L., and M. L. Lamson. 1987. RSTRIP user handbook, version 3.0. Micromath Inc., Salt Lake City, Utah.
16. Friedrich, L. V., R. L. White, M. B. Kays, D. M. Brundage, and D. Yarbrough III. 1991. Aztreonam pharmacokinetics in burn patients. Antimicrob. Agents Chemother. 35:57-61.
17. Garrelts, J. C., and J. D. Peterie. 1988. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin. Pharmacol. Ther. 44:9-13.
18. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics. Marcel Dekker, Inc., New York, N.Y.
19. Glew, R. H., R. C. Moellering, and J. F. Burke. 1976. Gentamicin dosage in children with extensive burns. J. Trauma 16:819-823.
20. Hoey, L. L., S. J. Tschida, J. C. Rotschafer, D. R. Guay, and K. Vance-Bryan. 1997. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J. Burn Care Rehabil. 18:116-124.
21. Jaehde, U., and F. Sörgel. 1995. Clinical pharmacokinetics in patients with burns. Clin. Pharmacokinet. 29:15-28.
22. Leeder, J. S., M. Spino, A. F. Isles, A. M. Tesoro, R. Gold, and S. M. MacLeod. 1984. Ceftazidime disposition in acute and stable cystic fibrosis. Clin. Pharmacol. Ther. 36:355-362.
23. Loirat, P., J. Rohan, A. Baillet, F. Beaufils, R. David, and A. Chapman. 1978. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N. Engl. J. Med. 299:915-919.
24. Martyn, J. A. J., D. R. Abernethy, and D. J. Greenblatt. 1984. Plasma protein binding of drugs after severe burn injury. Clin. Pharmacol. Ther. 35:535-539.
25. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S9, vol. 19, no. 1. National Committee for Clinical Laboratory Standards. Villanova, Pa.
26. Peck, M. D., and C. G. Ward. 1997. Burn injury, p. 1265-1275. In J. M. Civetta, R. W. Taylor, and R. R. Kirby (ed.), Critical care. Lippincott-Raven Publishers, Philadelphia, Pa.
27. Polk, R. E., C. G. Mayhall, J. Smith, G. Hall, B. J. Mine, E. Swensson, and B. W. Haynes. 1983. Gentamicin and tobramycin penetration into burn eschar. Arch. Surg. 118:295-302.
28. Rybak, M. J., L. M. Albrecht, J. R. Berman, L. H. Warbasse, and C. K. Svensson. 1990. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob. Agents Chemother. 34:792-795.
29. Sanders, C. C. 1993. Cefepime: the next generation? Clin. Infect. Dis. 17: 369-379.
30. Sawchuk, R. J., and D. E. Zaske. 1976. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet. Biopharm. 4:183-195.
31. Schentag, J. J. 1992. Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics. Infect. Med. 9(Suppl. B):10-12.
32. Shikuma, L. R., B. H. Ackerman, R. H. Weaver, L. D. Solem, R. G. Strate, F. B. Cerra, and D. W. Zaske. 1990. Thermal injury effects on drug disposition: a prospective study with piperacillin. J. Clin. Pharmacol. 30:632-637.
33. Walstad, R. A., L. Aanderud, and E. Thurmann-Nielsen. 1988. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur. J. Clin. Pharmacol. 35:543-549.
34. Yamaoko, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.
35. Zaske, D. E., R. J. Sawchuk, D. N. Gerding, and R. G. Strate. 1976. Increased dosage requirements of gentamicin in burn patients. J. Trauma 16:824-828.
36. Zaske, D. E., R. J. Sawchuk, and R. G. Strate. 1978. The necessity of increased doses of amikacin in burn patients. Surgery 84:603-608.
37. Zaske, D. E., J. L. Bootman, L. D. Solem, and R. G. Strate. 1982. Increased burn patient survival with individualized dosages of gentamicin. Surgery 91:142-149.